MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination
ABSTRACT Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated dise...
Gespeichert in:
| Veröffentlicht in: | Clinical kidney journal 2022-02, Vol.15 (2), p.357-359 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 359 |
|---|---|
| container_issue | 2 |
| container_start_page | 357 |
| container_title | Clinical kidney journal |
| container_volume | 15 |
| creator | Obata, Shota Hidaka, Sumi Yamano, Mizuki Yanai, Mitsuru Ishioka, Kunihiro Kobayashi, Shuzo |
| description | ABSTRACT
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We herein report a case of MPO-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis following the mRNA vaccine BNT162b2 (Pfizer/BioNTech) for COVID-19. Although the causal relationship between vaccine and ANCA-associated vasculitis is uncertain, environmental and genetic factors may have set the stage for the development of vasculitis, and the vaccine may have triggered a domino effect. |
| doi_str_mv | 10.1093/ckj/sfab181 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8500057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A766584644</galeid><oup_id>10.1093/ckj/sfab181</oup_id><sourcerecordid>A766584644</sourcerecordid><originalsourceid>FETCH-LOGICAL-c545t-93fbc184eec7f9af647edc0073d0b6a557c63d9c364f3bfb1825c507415d23663</originalsourceid><addsrcrecordid>eNp9kd1LHDEUxUNpqaI-9b0MFEqhjJtMvmZfCtOltoJ1pX68hsydGzd2drJOZgT9643sdqkgJg-55P7OITeHkA-MHjI65RP4ezOJztasZG_IbkFFmZeS8bfbmsodchDjDU0rdaiQ78kOl0wktdol899n87w6nVW5jTGAtwM22Z2NMLZ-8DGzbsA-GxaYnTn_gP3kuw-nFwiL7Lz6c57PwlVeJB7Ad3bwodsn75xtIx5szj1yefTjYvYrP5n_PJ5VJzlIIYd8yl0NrBSIoN3UOiU0NkCp5g2tlZVSg-LNFLgSjtcujVdIkFQLJpuCK8X3yLe172qsl0mK3dDb1qx6v7T9vQnWm-edzi_Mdbgz6UcolToZfNkY9OF2xDiYpY-AbWs7DGM0hSq00LqQPKGf1ui1bdH4zoXkCE-4qbRSshRKiEQdvkCl3eDSQ-jQ-XT_TPB1LYA-xNij276eUfMUrknhmk24if74_8Bb9l-UCfi8BsK4etXpEfDKq5k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627477253</pqid></control><display><type>article</type><title>MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination</title><source>Oxford Journals Open Access Collection</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Obata, Shota ; Hidaka, Sumi ; Yamano, Mizuki ; Yanai, Mitsuru ; Ishioka, Kunihiro ; Kobayashi, Shuzo</creator><creatorcontrib>Obata, Shota ; Hidaka, Sumi ; Yamano, Mizuki ; Yanai, Mitsuru ; Ishioka, Kunihiro ; Kobayashi, Shuzo</creatorcontrib><description>ABSTRACT
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We herein report a case of MPO-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis following the mRNA vaccine BNT162b2 (Pfizer/BioNTech) for COVID-19. Although the causal relationship between vaccine and ANCA-associated vasculitis is uncertain, environmental and genetic factors may have set the stage for the development of vasculitis, and the vaccine may have triggered a domino effect.</description><identifier>ISSN: 2048-8505</identifier><identifier>EISSN: 2048-8513</identifier><identifier>DOI: 10.1093/ckj/sfab181</identifier><identifier>PMID: 35140936</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Coronaviruses ; Exceptional Case ; Health aspects ; Pharmaceutical industry ; Prevention ; RNA ; Severe acute respiratory syndrome ; Vaccination ; Vasculitis</subject><ispartof>Clinical kidney journal, 2022-02, Vol.15 (2), p.357-359</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the ERA. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.</rights><rights>COPYRIGHT 2022 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c545t-93fbc184eec7f9af647edc0073d0b6a557c63d9c364f3bfb1825c507415d23663</citedby><cites>FETCH-LOGICAL-c545t-93fbc184eec7f9af647edc0073d0b6a557c63d9c364f3bfb1825c507415d23663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500057/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500057/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1598,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35140936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Obata, Shota</creatorcontrib><creatorcontrib>Hidaka, Sumi</creatorcontrib><creatorcontrib>Yamano, Mizuki</creatorcontrib><creatorcontrib>Yanai, Mitsuru</creatorcontrib><creatorcontrib>Ishioka, Kunihiro</creatorcontrib><creatorcontrib>Kobayashi, Shuzo</creatorcontrib><title>MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination</title><title>Clinical kidney journal</title><addtitle>Clin Kidney J</addtitle><description>ABSTRACT
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We herein report a case of MPO-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis following the mRNA vaccine BNT162b2 (Pfizer/BioNTech) for COVID-19. Although the causal relationship between vaccine and ANCA-associated vasculitis is uncertain, environmental and genetic factors may have set the stage for the development of vasculitis, and the vaccine may have triggered a domino effect.</description><subject>Coronaviruses</subject><subject>Exceptional Case</subject><subject>Health aspects</subject><subject>Pharmaceutical industry</subject><subject>Prevention</subject><subject>RNA</subject><subject>Severe acute respiratory syndrome</subject><subject>Vaccination</subject><subject>Vasculitis</subject><issn>2048-8505</issn><issn>2048-8513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kd1LHDEUxUNpqaI-9b0MFEqhjJtMvmZfCtOltoJ1pX68hsydGzd2drJOZgT9643sdqkgJg-55P7OITeHkA-MHjI65RP4ezOJztasZG_IbkFFmZeS8bfbmsodchDjDU0rdaiQ78kOl0wktdol899n87w6nVW5jTGAtwM22Z2NMLZ-8DGzbsA-GxaYnTn_gP3kuw-nFwiL7Lz6c57PwlVeJB7Ad3bwodsn75xtIx5szj1yefTjYvYrP5n_PJ5VJzlIIYd8yl0NrBSIoN3UOiU0NkCp5g2tlZVSg-LNFLgSjtcujVdIkFQLJpuCK8X3yLe172qsl0mK3dDb1qx6v7T9vQnWm-edzi_Mdbgz6UcolToZfNkY9OF2xDiYpY-AbWs7DGM0hSq00LqQPKGf1ui1bdH4zoXkCE-4qbRSshRKiEQdvkCl3eDSQ-jQ-XT_TPB1LYA-xNij276eUfMUrknhmk24if74_8Bb9l-UCfi8BsK4etXpEfDKq5k</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Obata, Shota</creator><creator>Hidaka, Sumi</creator><creator>Yamano, Mizuki</creator><creator>Yanai, Mitsuru</creator><creator>Ishioka, Kunihiro</creator><creator>Kobayashi, Shuzo</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220201</creationdate><title>MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination</title><author>Obata, Shota ; Hidaka, Sumi ; Yamano, Mizuki ; Yanai, Mitsuru ; Ishioka, Kunihiro ; Kobayashi, Shuzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c545t-93fbc184eec7f9af647edc0073d0b6a557c63d9c364f3bfb1825c507415d23663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Coronaviruses</topic><topic>Exceptional Case</topic><topic>Health aspects</topic><topic>Pharmaceutical industry</topic><topic>Prevention</topic><topic>RNA</topic><topic>Severe acute respiratory syndrome</topic><topic>Vaccination</topic><topic>Vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Obata, Shota</creatorcontrib><creatorcontrib>Hidaka, Sumi</creatorcontrib><creatorcontrib>Yamano, Mizuki</creatorcontrib><creatorcontrib>Yanai, Mitsuru</creatorcontrib><creatorcontrib>Ishioka, Kunihiro</creatorcontrib><creatorcontrib>Kobayashi, Shuzo</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical kidney journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Obata, Shota</au><au>Hidaka, Sumi</au><au>Yamano, Mizuki</au><au>Yanai, Mitsuru</au><au>Ishioka, Kunihiro</au><au>Kobayashi, Shuzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination</atitle><jtitle>Clinical kidney journal</jtitle><addtitle>Clin Kidney J</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>15</volume><issue>2</issue><spage>357</spage><epage>359</epage><pages>357-359</pages><issn>2048-8505</issn><eissn>2048-8513</eissn><abstract>ABSTRACT
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We herein report a case of MPO-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis following the mRNA vaccine BNT162b2 (Pfizer/BioNTech) for COVID-19. Although the causal relationship between vaccine and ANCA-associated vasculitis is uncertain, environmental and genetic factors may have set the stage for the development of vasculitis, and the vaccine may have triggered a domino effect.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>35140936</pmid><doi>10.1093/ckj/sfab181</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2048-8505 |
| ispartof | Clinical kidney journal, 2022-02, Vol.15 (2), p.357-359 |
| issn | 2048-8505 2048-8513 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8500057 |
| source | Oxford Journals Open Access Collection; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Coronaviruses Exceptional Case Health aspects Pharmaceutical industry Prevention RNA Severe acute respiratory syndrome Vaccination Vasculitis |
| title | MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T14%3A03%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MPO-ANCA-associated%20vasculitis%20after%20the%20Pfizer/BioNTech%20SARS-CoV-2%20vaccination&rft.jtitle=Clinical%20kidney%20journal&rft.au=Obata,%20Shota&rft.date=2022-02-01&rft.volume=15&rft.issue=2&rft.spage=357&rft.epage=359&rft.pages=357-359&rft.issn=2048-8505&rft.eissn=2048-8513&rft_id=info:doi/10.1093/ckj/sfab181&rft_dat=%3Cgale_pubme%3EA766584644%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627477253&rft_id=info:pmid/35140936&rft_galeid=A766584644&rft_oup_id=10.1093/ckj/sfab181&rfr_iscdi=true |